NL-OMON39486已完成不适用
Towards optimizing infliximab therapy in severe sarcoidosis patients: personalized medicine - Infliximab in sarcoidosis patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- patients diagnosed with sarcoidosis.
- •- patients treated with infliximab
- •- capability of giving informed consent
排除标准
- •· vaccination with live viral or bacterial vaccines within the previous 3 months, or within the next 3 months of the last doses.
- •· cases of active or untreated latent tuberculosis (by mantoux-Elispot/TBC-IGRA)
- •· serious infections within the past 2 months
- •· serious right-sided heart failure or cor polmunale
- •· known malignancy
- •· Hepatitis B
- •· paitients with allergic reactions to the monocolonal antibodies or their fragments
- •· oppotunistic infections last 6 months
- •· transplantation
- •· pregnancy or bearstfeeding
研究者
相似试验
招募中
不适用
Towards optimizing infliximab therapyin severe sarcoidosis patients:personalized medicine.Sarcoidosis, treatment, infliximabNL-OMON29326St Antonius Hospital Nieuwegein52
进行中（未招募）
不适用
Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingSarcoidosisEUCTR2014-002224-26-NLSt. Antonius Hospital
撤回
4 期
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment1002766510024967SarcoidosisNL-OMON42033Sint Antonius Ziekenhuis70
进行中（未招募）
不适用
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-DKSchering-Plough Research Institute, a Division of Schering Corporation150
进行中（未招募）
1 期
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-BESchering-Plough Research Institute, a Division of Schering Corporation150